JMPWA
BCLI

JP Morgan Private Wealth Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,565
Closed -$471K – 1241
2017
Q2 		$471K Buy
+7,565
New +$466K ﹤0.01% 856

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Private Wealth Advisors's BCLI Position: Q3 2017 in Review

JP Morgan Private Wealth Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2017, closing a stake of 7,565 shares — an estimated $471K sold.

JP Morgan Private Wealth Advisors first reported a position in BCLI in Q2 2017 and held it in 1 quarter. The position peaked at $471K in Q2 2017. 32 funds tracked by Wall St. Rank hold BCLI as of Q3 2017.

  • JP Morgan Private Wealth Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2017 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 7,565 BRAINSTORM CELL THERAPUTC shares in Q3 2017, an estimated $471K.
  • JP Morgan Private Wealth Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2017 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's BRAINSTORM CELL THERAPUTC position peaked at $471K in Q2 2017.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2017.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.